

(19)  Canadian
Intellectual Property
Office

An Agency of
Industry Canada

Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

(11) **CA 2 357 771** (13) **A1**

(40) 13.07.2000

(43) 13.07.2000

(12)

(21) 2 357 771

(22) 21.12.1999

(51) Int. Cl. 7: **C07D 471/04, C07D 221/00,
C07D 235/00, A61P 9/10,
A61K 31/437**

(85) 06.07.2001

(86) PCT/EP99/10236

(87) WO00/40583

(30) 199 00 471.4 DE 08.01.1999

(71) MERCK PATENT GESELLSCHAFT MIT
BESCHRANKTER HAFTUNG,
Frankfurter Strasse 250
64271, DARMSTADT, XX (DE).

MEDERSKI, WERNER (DE).
WURZIGER, HANNS (DE).
JURASZYK, HORST (DE).
DORSCH, DIETER (DE).
BERNOTAT-DANIELOWSKI, SABINE (DE).
MELZER, GUIDO (DE).
ANZALI, SOHEILA (DE).

(72) TSAKLAKIDIS, CHRISTOS (DE).


(74) FETHERSTONHAUGH & CO.

(54) DERIVES D'IMIDAZO[4,5-C]PYRIDINE-4-ONE

(54) IMIDAZO[4,5-C]-PYRIDINE-4-ONE DERIVATIVES

(57)

²²²²The invention relates to novel compounds of
formula (1) wherein R, R¹, R², R³ and n have the
meaning given in Claim 1. Said compounds are inhibitors
of the coagulation factor Xa and can be used for the
prophylaxis and/or therapy of thrombo-embolic
diseases.²





Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2357771 A1 2000/07/13

(21) 2 357 771

(12) DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION

(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 1999/12/21
(87) Date publication PCT/PCT Publication Date: 2000/07/13
(85) Entrée phase nationale/National Entry: 2001/07/06
(86) N° demande PCT/PCT Application No.: EP 99/10236
(87) N° publication PCT/PCT Publication No.: WO 00/40583
(30) Priorité/Priority: 1999/01/08 (199 00 471.4) DE


(51) Cl.Int.⁷/Int.Cl.⁷ C07D 471/04, A61K 31/437, A61P 9/10,
C07D 235/00, C07D 221/00

(71) Demandeur/Applicant:
MERCK PATENT GESELLSCHAFT MIT
BESCHRANKTER HAFTUNG, DE

(72) Inventeurs/Inventors:
ANZALI, SOHEILA, DE;
MELZER, GUIDO, DE;
BERNOTAT-DANIELOWSKI, SABINE, DE;
DORSCH, DIETER, DE;
TSAKLAKIDIS, CHRISTOS, DE;
WURZIGER, HANNS, DE;
JURASZYK, HORST, DE;
MEDERSKI, WERNER, DE

(54) Titre : DERIVES D'IMIDAZO[4,5-C]PYRIDINE-4-ONE

(54) Title: IMIDAZO[4,5-C]-PYRIDINE-4-ONE DERIVATIVES



(57) Abrégé/Abstract:

The invention relates to novel compounds of formula (I) wherein R, R¹, R², R³ and n have the meaning given in Claim 1. Said compounds are inhibitors of the coagulation factor Xa and can be used for the prophylaxis and/or therapy of thrombo-embolic diseases.

Canada

<http://opic.gc.ca> • Ottawa-Hull K1A 0C9 • <http://cipo.gc.ca>

OPIC • CIPQ 191

OPIC



CIPQ

(74) Agent: FETHERSTONHAUGH & CO.




PCT
WELTORGANISATION FÜR GEISTIGES EIGENTUM
Internationales Büro
INTERNATIONALE ANMELDUNG VERÖFFENTLICHT NACH DEM VERTRAG ÜBER DIE
INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT)


<p>(51) Internationale Patentklassifikation ⁷ : C07D 471/04, A61K 31/437, A61P 9/10 // (C07D 471/04, 235:00, 221:00)</p>	A3	<p>(11) Internationale Veröffentlichungsnummer: WO 00/40583</p> <p>(43) Internationales Veröffentlichungsdatum: 13. Juli 2000 (13.07.00)</p>
<p>(21) Internationales Aktenzeichen: PCT/EP99/10236</p> <p>(22) Internationales Anmeldedatum: 21. Dezember 1999 (21.12.99)</p> <p>(30) Prioritätsdaten: 199 00 471.4 8. Januar 1999 (08.01.99) DE</p> <p>(71) Anmelder (für alle Bestimmungsstaaten ausser US): MERCK PATENT GMBH [DE/DE]; Frankfurter Strasse 250, D-64293 Darmstadt (DE).</p> <p>(72) Erfinder; und</p> <p>(75) Erfinder/Anmelder (nur für US): MEDERSKI, Werner [DE/DE]; Am Ohlenberg 29, D-64390 Erzhausen (DE). JURASZYK, Horst [DE/DE]; Kleiner Ring 14, D-64342 Seeheim (DE). WURZIGER, Hanns [DE/DE]; Grein-strasse 7b, D-64291 Darmstadt (DE). TSAKLAKIDIS, Christos [GR/DE]; Rosenbrunnenstrasse 25, D-69469 Weinheim (DE). DORSCH, Dieter [DE/DE]; Königsberger Strasse 17a, D-64372 Ober-Ramstadt (DE). BERNO-TAT-DANIELOWSKI, Sabine [DE/DE]; Liebigstrasse 5, D-61231 Bad Neuheim (DE). MELZER, Guido [AT/DE]; Mörikestrasse 6, D-65719 Hofheim (DE). ANZALI, Soheila [IR/DE]; Am Alten Berg 13, D-64342 Seeheim (DE).</p>	<p>(74) Gemeinsamer Vertreter: MERCK PATENT GMBH; D-64271 Darmstadt (DE).</p> <p>(81) Bestimmungsstaaten: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO Patent (GH, GM, KE, LS, MW, SD, SL, SZ, T7, UG, ZW), eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), europäisches Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Veröffentlicht <i>Mit internationalem Recherchenbericht.</i></p> <p>(88) Veröffentlichungsdatum des internationalen Recherchenberichts: 21. September 2000 (21.09.00)</p>	
<p>(54) Title: IMIDAZO[4,5-C]-PYRIDINE-4-ON-DERIVATIVES</p> <p>(54) Bezeichnung: IMIDAZO[4,5-C]-PYRIDIN-4-ON-DERIVATE</p>		
<p>(57) Abstract</p> <p>The invention relates to novel compounds of formula (I) wherein R, R¹, R², R³ and n have the meaning given in Claim 1. Said compounds are inhibitors of the coagulation factor Xa and can be used for the prophylaxis and/or therapy of thrombo-embolic diseases.</p> <p>(57) Zusammenfassung</p> <p>Neue Verbindungen der Formel (I), worin R, R¹, R², R³ und n die in Patentanspruch 1 angegebene Bedeutung haben, sind Inhibitoren des Koagulationsfaktors Xa und können zur Prophylaxe und/oder Therapie von thromboembolischen Erkrankungen eingesetzt werden.</p>		

Imidazo[4,5-c]pyridin-4-one derivatives

The invention relates to compounds of the formula I



- 5 in which
 R is H or unbranched or branched alkyl having 1-6 C atoms or cycloalkyl having 3-6 C atoms,
 R¹ is Ar,
 R² is Ar',
 10 R³ is H, R, R⁴, Hal, CN, COOH, COOA or CONH₂,
 Ar, Ar' are phenyl, naphthyl or biphenyl, in each case independently of one another unsubstituted or mono-, di- or trisubstituted by R, OH, Hal, CN, NO₂, CF₃, NH₂, NHR, NR₂, pyrrolidin-1-yl,
 15 piperidin-1-yl, benzyloxy, SO₂NH₂, SO₂NHR, SO₂NR₂, -CONHR, -CONR₂, -(CH₂)_n-NH₂, -(CH₂)_n-NHR, -(CH₂)_n-NR₂, -O-(CH₂)_n-NH₂, -O-(CH₂)_n-NHR, -O-(CH₂)_n-NR₂, R⁴ or together by -O-(CH₂)_m-O-, or are NH₂-substituted isoquinolinyl,
 20 R⁴ is -C(=NH)-NH₂ which is unsubstituted or monosubstituted by -COR, -COOR, -OH or by a conventional amino protective group or -NH-C(=NH)-NH₂, -C(=O)-N=C(NH₂)₂,



- 25 A is alkyl having 1-4 C atoms,
 Hal is F, Cl, Br or I,
 m is 1 or 2,
 n is 0 or 1,

30 and their salts and solvates.

- 2 -

The invention also relates to the optically active forms, the racemates, the diastereomers and the hydrates and solvates, e.g. alcoholates, of these compounds.

5

The invention is based on the object of finding novel compounds having useful properties, in particular those which can be used for the production of medicaments.

10 It has been found that the compounds of the formula I and their salts have very useful pharmacological properties together with good tolerability. In particular, they show factor Xa-inhibiting properties and can therefore be employed for the control and
15 prevention of thromboembolic disorders such as thrombosis, myocardial infarct, arteriosclerosis, inflammations, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication.

20 The compounds of the formula I according to the invention can furthermore be inhibitors of the clotting factors factor VIIa, factor IXa and thrombin of the blood clotting cascade.

25 Aromatic amidine derivatives having antithrombotic action are disclosed, for example, in EP 0 540 051 B1. Cyclic guanidines for the treatment of thromboembolic disorders are described, for example, in WO 97/08165. Aromatic heterocycles having factor Xa-inhibitory
30 activity are disclosed, for example, in WO 96/10022. Substituted N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclamides as factor Xa inhibitors are described in WO 96/40679.

35 The antithrombotic and anticoagulating effect of the compounds according to the invention is attributed to the inhibiting action against the activated clotting protease, known under the name factor Xa, or to the

- 3 -

inhibition of other activated serine proteases such as factor VIIa, factor IXa or thrombin.

Factor Xa is one of the proteases which is involved in the complex process of blood clotting. Factor Xa catalyses the conversion of prothrombin into thrombin. Thrombin cleaves fibrinogen into fibrin monomers which, after crosslinking, contribute elementarily to thrombus formation. Activation of thrombin can lead to the occurrence of thromboembolic disorders. Inhibition of thrombin, however, can inhibit the fibrin formation involved in thrombus formation.

The inhibition of thrombin can be measured, for example, by the method of G.F. Cousins et al. in *Circulation* 1996, 94, 1705-1712.

Inhibition of factor Xa can thus prevent thrombin being formed.

The compounds of the formula I according to the invention and their salts intervene in the blood clotting process by inhibition of factor Xa and thus inhibit the formation of thrombi.

The inhibition of factor Xa by the compounds according to the invention and the anticoagulating and antithrombotic activity can be determined by customary in vitro or in vivo methods. A suitable procedure is described, for example, by J. Hauptmann et al. in *Thrombosis and Haemostasis* 1990, 63, 220-223.

The inhibition of factor Xa can be measured, for example, by the method of T. Hara et al. in *Thromb. Haemostas.* 1994, 71, 314-319.

After binding to tissue factor, the clotting factor VIIa initiates the extrinsic part of the clotting cascade and contributes to the activation of factor X to factor Xa. Inhibition of factor VIIa thus prevents

- 4 -

the formation of factor Xa and thus subsequent thrombin formation.

5 The inhibition of factor VIIa by the compounds according to the invention and the anticoagulating and antithrombotic activity can be determined by customary in vitro or in vivo methods. A customary procedure for the measurement of the inhibition of factor VIIa is described, for example, by H.F. Ronning et al. in *Thrombosis Research* 1996, 84, 73-81.

10

The clotting factor IXa is generated in the intrinsic clotting cascade and is likewise involved in the activation of factor X to factor Xa. Inhibition of factor IXa can therefore prevent factor Xa being formed in another way.

15

The inhibition of factor IXa by the compounds according to the invention and the anticoagulating and antithrombotic activity can be determined by customary in vitro or in vivo methods. A suitable procedure is described, for example, by J. Chang et al. in *Journal of Biological Chemistry* 1998, 273, 12089-12094.

20

The compounds of the formula I can be employed as pharmaceutical active compounds in human and veterinary medicine, in particular for the control and prevention of thromboembolic disorders such as thrombosis, myocardial infarct, arteriosclerosis, inflammations, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication.

25

The invention relates to the compounds of the formula I and their salts, and to a process for the preparation of compounds of the formula I according to Claim 1 and their salts, characterized in that

30

- 35 a) they are set free from one of their functional derivatives by treating with a solvolysing or hydrogenolysing agent, by

- 5 -

- i) liberating an amidino group from its oxadiazole derivative or oxazolidinone derivative by hydrogenolysis or solvolysis,
- 5 ii) replacing a conventional amino protective group by hydrogen by treating with a solvolysing or hydrogenolysing agent or liberating an amino group protected by a conventional protective group,
- 10 or
- b) in a compound of the formula I, one or more radicals R, R¹, R² and/or R³ are converted into one
- 15 or more radicals R, R¹, R² and/or R³,
- by, for example
- i) hydrolysing an ester group to a carboxyl group
- 20 ii) reducing a nitro group
- iii) acylating an amino group
- iv) converting a cyano group into an amidino group
- 25 and/or
- c) a base or acid of the formula I is converted into
- 30 one of its salts.

For all radicals which occur a number of times, it is a condition that their meanings are independent of one another.

35

Above and below, the radicals and parameters R, R¹, R², R³ and n have the meanings indicated in the formula I, if not expressly stated otherwise.

- 6 -

R is alkyl, is unbranched (linear) or branched, and has 1 to 6, preferably 1, 2, 3, 4, 5 or 6, C atoms. R is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, in addition also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl. R is also cycloalkyl and is preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

A is alkyl having 1, 2, 3 or 4 C atoms and is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl.

Hal is preferably F, Cl or Br, but also I.

Ar and Ar' are phenyl, benzodioxol-5-yl, naphthyl or biphenyl, in each case independently of one another unsubstituted or mono-, di- or trisubstituted by R, OH, OR, Hal, CN, NO₂, CF₃, NH₂, NHR, NR₂, pyrrolidin-1-yl, piperidin-1-yl, benzyloxy, SO₂NH₂, SO₂NHA, SO₂NR₂, phenylsulfonamido, -(CH₂)_n-NH₂, -(CH₂)_n-NHR, -(CH₂)_n-NR₂, -O-(CH₂)_n-NH₂, -O-(CH₂)_n-NHR, -O-(CH₂)_n-NR₂, -O-(CH₂)_m-O- or R⁴, naphthyl or biphenyl monosubstituted by amidino being preferred. Preferred substituents for biphenyl are amidino, fluorine, SO₂NH₂ or SO₂NHR.

Ar and Ar' are phenyl, naphthyl or biphenyl, in each case independently of one another preferably unsubstituted, phenyl, naphthyl or biphenyl, furthermore preferably, for example, mono-, di- or trisubstituted by methyl, ethyl, propyl, isopropyl, butyl, cyclopentyl, cyclohexyl, fluorine, chlorine, bromine, iodine, hydroxyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, cyano, nitro, trifluoromethyl, amino, methylamino, ethylamino,

- 7 -


- dimethylamino, diethylamino, pyrrolidin-1-yl,
 piperidin-1-yl, benzyloxy, sulfonamido,
 methylsulfonamido, ethylsulfonamido, propylsulfonamido,
 butylsulfonamido, dimethylsulfonamido, phenylsulfon-
 amido, aminomethyl, aminoethyl, N-methylaminomethyl, N-
 ethylaminomethyl, N,N-dimethylaminomethyl, amino-
 methyloxy, aminoethyloxy or R⁴ and in addition
 benzodioxolyl.
- 10 Ar and Ar' are therefore, in each case independently of
 one another, very particularly preferably, for example,
 o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or
 p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or
 p-tert-butylphenyl, o-, m- or p-hydroxyphenyl, o-, m-
 or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p-
 (N-methylamino)phenyl, o-, m- or p-(N-methylamino-
 carbonyl)phenyl, o-, m- or p-acetamidophenyl, o-, m- or
 p-methoxyphenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-
 (N,N-dimethylamino)phenyl, o-, m- or p-(N,N-
 dimethylaminocarbonyl)phenyl, o-, m- or p-(N-
 ethylamino)phenyl, o-, m- or p-(N,N-
 diethylamino)phenyl, o-, m- or p-fluorophenyl, o-, m-
 or p-bromophenyl, o-, m- or p-chlorophenyl, o-, m- or
 p-(methylsulfonamido)phenyl, o-, m- or p-amidinophenyl,
 7-amidino-2-naphthyl, 2'-amidinobiphenyl-3-yl, 3-
 fluoro-2'-sulfamoylbiphenyl-4-yl, 3-fluoro-2'-N-tert-
 butylsulfamoylbiphenyl-4-yl, 2'-sulfamoylbiphenyl-4-yl,
 2'-N-tert-butylsulfamoylbiphenyl-4-yl, o-, m- or p-
 (pyrrolidin-1-yl)phenyl, o-, m- or p-(piperidin-1-
 yl)phenyl, o-, m- or p-(5-methyl[1,2,4]oxadiazol-3-
 yl)phenyl, 7-(5-methyl[1,2,4]oxadiazol-3-yl)naphth-2-
 yl, o-, m- or p-(5-oxo[1,2,4]oxadiazol-3-yl)phenyl, 7-
 (5-oxo[1,2,4]oxadiazol-3-yl)naphth-2-yl, furthermore
 preferably 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-
 difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-
 dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-
 dibromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or 3,4-
 dimethoxyphenyl, 3-nitro-4-chlorophenyl, 3-amino-4-
 chloro-, 2-amino-3-chloro-, 2-amino-4-chloro-, 2-amino-

- 8 -


5-chloro- or 2-amino-6-chlorophenyl, 2-nitro-4-N,N-dimethylamino- or 3-nitro-4-N,N-dimethylaminophenyl, 2,3-diaminophenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, 2,4,6-trimethoxyphenyl, 2-hydroxy-3,5-dichlorophenyl, p-iodophenyl, 3,6-dichloro-4-aminophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4-bromophenyl, 2,5-difluoro-4-bromophenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-methoxyphenyl, 3-chloro-4-acetamidophenyl, 3-fluoro-4-methoxyphenyl, 3-amino-6-methylphenyl, 3-chloro-4-acetamidophenyl or 2,5-dimethyl-4-chlorophenyl.

R^3 is preferably, for example, H, Hal, COOH, COOA or CONH₂.

R^4 is preferably, for example, unsubstituted -C(=NH)-NH₂, -NH-C(=NH)-NH₂, -C(=O)-N=C(NH₂)₂, which can also be monosubstituted by OH,




very particularly preferably unsubstituted or OH-substituted -C(=NH)-NH₂ or




m is 1 or 2.

25 n is preferably 0 or 1.



- 9 -




The compounds of the formula I can have one or more chiral centres and therefore occur in various stereoisomeric forms. The formula I includes all these forms.

5

Accordingly, the invention relates in particular to those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above. Some preferred groups of compounds can be expressed by the following subformulae Ia to Ii, which correspond to the formula I and in which the radicals not designated in greater detail have the meaning indicated in the formula I, but in which

15

- | | | |
|----------|----------------|---|
| in Ia | Ar | is phenyl, naphthyl or biphenyl which is monosubstituted by R ⁴ ; |
| in Ib | Ar' | is phenyl, naphthyl or biphenyl which is monosubstituted by SO ₂ NH ₂ or R ⁴ ; |
| 20 in Ic | Ar, Ar' | are phenyl, naphthyl or biphenyl, in each case independently of one another monosubstituted by SO ₂ NH ₂ or R ⁴ ; |
| in Id | Ar, Ar' | are phenyl, naphthyl or biphenyl, in each case independently of one another monosubstituted by -CONR ₂ , SO ₂ NH ₂ or R ⁴ ; |
| 25 in Ie | R ³ | is H, R, Hal, COOH or COOA; |
| in If | R ⁴ | is SO ₂ NH ₂ or -C(=NH)-NH ₂ or |




- 10 -

- in Ig R is unbranched or branched alkyl having 1-6 C atoms or cycloalkyl having 3-6 C atoms,
- 5 R¹ is Ar,
R² is Ar',
R³ is H, R, Hal, COOH or COOA,
Ar, Ar' are phenyl, naphthyl or biphenyl, in each case independently of one another monosubstituted by -CONR₂, SO₂NH₂ or R⁴,
- 10 R⁴ is -C(=NH)-NH₂ or
- Cc1nnoc1
- 15 A is alkyl having 1-4 C atoms,
Hal is F, Cl, Br or I,
m is 1 or 2,
n is 0 or
- in Ih R is H or unbranched or branched alkyl having 1-6 C atoms or cycloalkyl having 3-6 C atoms,
- 20 R¹ is Ar,
R² is Ar',
R³ is H, R, Hal, COOH or COOA,
Ar, Ar' are phenyl, naphthyl or biphenyl, in each case independently of one another monosubstituted by SO₂NH₂ or R⁴,
- 25 R⁴ is -C(=NH)-NH₂ or
- Cc1nnoc1
- 30 A is alkyl having 1-4 C atoms,
Hal is F, Cl, Br or I,
m is 1 or 2,
n is 0 or 1;
- in Ii R is H or unbranched or branched alkyl having 1-6 C atoms or cycloalkyl having 3-6 C atoms,

- 11 -

R^1 is Ar,
 R^2 is Ar',
 R^3 is H, R, Hal, COOH or COOA,
 Ar, Ar' are phenyl, naphthyl or biphenyl, in
 each case independently of one another
 monosubstituted by SO_2NHR or R^4 ,
 or are NH_2 -substituted isoquinolinyl,
 R^4 is unsubstituted or OH-substituted
 $-C(=NH)-NH_2$ or



A is alkyl having 1-4 C atoms,
 Hal is F, Cl, Br or I,
 m is 1 or 2,
 n is 0 or 1.

The compounds of the formula I and also the starting
 substances for their preparation are otherwise prepared
 by methods known per se, such as are described in the
 literature (e.g. in the standard works such as Houben-
 Weyl, Methoden der organischen Chemie [Methods of
 Organic Chemistry], Georg-Thieme-Verlag, Stuttgart),
 namely under reaction conditions which are known and
 suitable for the reactions mentioned. Use can also be
 made in this case of variants which are known per se,
 but not mentioned here in greater detail.

The starting substances can, if desired, also be formed
 in situ, such that they are not isolated from the
 reaction mixture, but immediately reacted further to
 give the compounds of the formula I.

Compounds of the formula I can preferably be obtained
 by setting compounds of the formula I free from one of
 their functional derivatives by treating with a
 solvolysing or hydrogenolysing agent.

- 12 -

- Preferred starting substances for the solvolysis or hydrogenolysis are those which otherwise correspond to the formula I, but instead of one or more free amino and/or hydroxyl groups contain corresponding protected amino and/or hydroxyl groups, preferably those which, instead of an H atom which is bonded to an N atom, carry an amino protective group, in particular those which, instead of an HN group, carry an R'-N group in which R' is an amino protective group, and/or those which, instead of the H atom of a hydroxyl group, carry a hydroxyl protective group, e.g. those which correspond to the formula I, but instead of a group -COOH carry a group -COOR", in which R" is a hydroxyl protective group.
- Preferred starting substances are also the oxadiazole derivatives, which can be converted into the corresponding amidino compounds.

The amidino group can be liberated from its oxadiazole derivative, for example, by treating with hydrogen in the presence of a catalyst (e.g. Raney nickel). Suitable solvents are those indicated below, in particular alcohols such as methanol or ethanol, organic acids such as acetic acid or propionic acid, or mixtures thereof. As a rule, the hydrogenolysis is carried out at temperatures between approximately 0 and 100° and pressures between approximately 1 and 200 bar, preferably at 20-30° (room temperature) and 1-10 bar.

The oxadiazole group is introduced, for example, by reaction of the cyano compounds with hydroxylamine and reaction with phosgene, dialkyl carbonate, chloroformic acid esters, N,N'-carbonyldiimidazole or acetic anhydride.

A number of - identical or different - protected amino and/or hydroxyl groups can also be present in the molecule of the starting substance. If the protective

- 13 -

groups present are different from one another, in many cases they can be removed selectively.

The expression "amino protective group" is generally known and relates to groups which are suitable for protecting (for blocking) an amino group from chemical reactions, but which are easily removable after the desired chemical reaction has been carried out at other positions in the molecule. Typical groups of this type are, in particular, unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups. Since the amino protective groups are removed after the desired reaction (or reaction sequence), their nature and size is otherwise not critical; however, those having 1-20, in particular 1-8, C atoms are preferred. The expression "acyl group" is to be interpreted in the widest sense in connection with the present process. It includes acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulphonic acids and, in particular, alkoxycarbonyl, aryloxy carbonyl and especially aralkoxycarbonyl groups. Examples of acyl groups of this type are alkanoyl such as acetyl, propionyl, butyryl; aralkanoyl such as phenylacetyl; aroyl such as benzoyl or toluylyl; aryloxyalkanoyl such as POA; alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC (tert-butyloxycarbonyl), 2-iodoethoxycarbonyl; aralkyloxycarbonyl such as CBZ ("carbobenzoxyl"), 4-methoxybenzyloxycarbonyl, FMOC; arylsulfonyl such as Mtr. Preferred amino protective groups are BOC and Mtr, in addition CBZ, Fmoc, benzyl and acetyl.

The liberation of the compounds of the formula I from their functional derivatives is carried out - depending on the protective group used - for example using strong acids, expediently using TFA or perchloric acid, but also using other strong inorganic acids such as hydrochloric acid or sulphuric acid, strong organic

- 14 -

carboxylic acids such as trichloroacetic acid or sulphonic acids such as benzene- or p-toluenesulphonic acid. The presence of an additional inert solvent is possible, but not always necessary. Suitable inert solvents are preferably organic, for example carboxylic acids such as acetic acid, ethers such as tetrahydrofuran or dioxane, amides such as DMF, halogenated hydrocarbons such as dichloromethane, in addition also alcohols such as methanol, ethanol or isopropanol, and also water. Mixtures of the abovementioned solvents are additionally suitable. TFA is preferably used in an excess without addition of a further solvent, perchloric acid in the form of a mixture of acetic acid and 70% perchloric acid in the ratio 9:1. The reaction temperatures for the cleavage are expediently between approximately 0 and approximately 50°; the reaction is preferably carried out between 15 and 30° (room temperature).

The groups BOC, OBut and Mtr can be removed, for example, preferably using TFA in dichloromethane or using approximately 3 to 5N HCl in dioxane at 15-30°; the FMOC group using an approximately 5 to 50% solution of dimethylamine, diethylamine or piperidine in DMF at 15-30°.

Hydrogenolytically removable protective groups (e.g. CBZ, benzyl) can be removed or the amidino group can be liberated from its oxadiazole derivative, for example by treating with hydrogen in the presence of a catalyst (e.g. of a noble metal catalyst such as palladium, expediently on a support such as carbon). Suitable solvents here are those indicated above, in particular, for example, alcohols such as methanol or ethanol or amides such as DMF. As a rule, the hydrogenolysis takes place at temperatures between approximately 0 and 100° and pressures between approximately 1 and 200 bar, preferably at 20-30° and 1-10 bar. Hydrogenolysis of the CBZ group takes place readily, for example, on 5 to

- 15 -

10% Pd/C in methanol or using ammonium formate (instead of hydrogen) on Pd/C in methanol/DMF at 20-30°.

Suitable inert solvents are, for example, hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, trifluoromethylbenzene, chloroform or dichloromethane; alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); ketones such as acetone or butanone; amides such as acetamide, dimethylacetamide, N-methylpyrrolidone (NMP) or dimethylformamide (DMF); nitriles such as acetonitrile; sulfoxides such as dimethyl sulfoxide (DMSO); carbon disulphide; carboxylic acids such as formic acid or acetic acid; nitro compounds such as nitromethane or nitrobenzene; esters such as ethyl acetate or mixtures of the solvents mentioned.

The biphenyl-SO₂NH₂ group is preferably employed in the form of its tert-butyl derivative. The tert-butyl group is removed, for example, using TFA with or without addition of an inert solvent, preferably with addition of a small amount of anisole (1% by volume).

The cyano group is converted into an amidino group by reaction with, for example, hydroxylamine and subsequent reduction of the N-hydroxyamidine with hydrogen in the presence of a catalyst such as, for example, Pd/C.

For the preparation of an amidine of the formula I (e.g. Ar = phenyl monosubstituted by C(=NH)-NH₂), ammonia can also be added to a nitrile. The addition is preferably carried out in a number of stages in a manner known per se by a) converting the nitrile using


- 16 -

H₂S into a thioamide, which is converted using an alkylating agent, e.g. CH₃I, into the corresponding S-alkyl imidothioester, which for its part is reacted with NH₃ to give the amidine, b) converting the nitrile into the corresponding imido ester using an alcohol, e.g. ethanol in the presence of HCl, and treating this with ammonia, or c) reacting the nitrile with lithium bis(trimethylsilyl)amide and then hydrolysing the product.

10

The radical R¹ (if n=0) or R² is introduced into the dihydroimidazo[4,5-c]pyridin-4-one system by N-arylation (Lit.: Chan et al., Tetrahedron Letters 1998, 39, 2933ff and 2941ff).


15 Thus it is possible, for example, for preparing compounds of the formula (IA) to react a compound of the formula II



20


in which R has the meaning indicated in Claim 1 and R¹ and R³ are each a radical of the type which cannot be alkylated, such as, for example, for R¹ a phenyl, benzyl or

naphthyl radical substituted by




25

with a compound of the formula III



- 17 -


This gives compounds of the formula IV



5 These are then reacted further to give the compounds according to the invention.


Suitable solvents are those mentioned above. The reaction is carried out in the presence of , for example, Cu(II)(OAc)₂. Depending on the conditions used, the reaction time is between a few minutes and 14 days, and the reaction temperature is between approximately 0° and 150°, normally between 15° and 80°.

15 Analogously, R² can also firstly be introduced into the dihydroimidazole (4,5-c)pyridin-4-one system and then a compound of the formula (V)



20 in which R has the meaning indicated in Claim 1 and R² and R³ are each a radical of the type which cannot be alkylated,

25 can be reacted with a compound of the formula VI



In the compounds of the formula VI, n is 1, R¹ is a radical which cannot be alkylated, such as, for

- 18 -

example, a phenyl radical substituted by 5-methyl[1,2,4]oxadiazol-3-yl, and L is Cl, Br, I or a free or reactive functionally modified OH group.


L is preferably Cl, Br, I or a reactive modified OH group, such as, for example, an activated ester, an imidazolide or alkylsulfonyloxy having 1-6 C atoms (preferably methylsulfonyloxy) or arylsulfonyloxy having 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy).

10


This process gives compounds of the formula (IA) and/or (IB).

If compounds of the formula II in which n is 0 are reacted with compounds of the formula VII

15




compounds of the formula VIII



20


are obtained.

Subsequent reaction of the compounds of the formula VIII with compounds of the formula IX



25

gives compounds of the formula X



The compounds of the formula I are subsequently obtained by cleaving off the tert-butyl group and conversion of the oxidiazole radical into an amidino group.

In addition, it is possible to convert a compound of the formula I into another compound of the formula I by converting one or more radicals R, R¹, R² and/or R³ into one or more radicals R, R¹, R² and/or R³, e.g. by acylating an amino group or reducing nitro groups (for example by hydrogenation on Raney nickel or Pd-carbon in an inert solvent such as methanol or ethanol) to amino groups.

Esters can be hydrolysed, for example, using acetic acid or using NaOH or KOH in water, water-THF or water-dioxane at temperatures between 0 and 100°.

In addition, free amino groups can be acylated in a customary manner using an acid chloride or anhydride or alkylated using an unsubstituted or substituted alkyl halide, expediently in an inert solvent such as dichloromethane or THF and/or in the presence of a base such as triethylamine or pyridine at temperatures between -60 and +30°.

A base of the formula I can be converted into the associated acid addition salt using an acid, for example by reaction of equivalent amounts of the base and of the acid in an inert solvent such as ethanol and subsequent evaporation. Acids suitable for this

- 20 -

reaction are in particular those which yield physiologically acceptable salts. Thus, inorganic acids can be used, e.g. sulphuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or
5 hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulphamic acid, in addition organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulphonc or sulphuric acids,
10 e.g. formic acid, acetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid,
15 methane- or ethanesulphonic acid, ethanedisulphonic acid, 2-hydroxyethanesulphonic acid, benzenesulphonic acid, p-toluenesulphonic acid, naphthalenemono- and -disulphonic acids, and laurylsulphonic acid. Salts with physiologically unacceptable acids, e.g. picrates,
20 can be used for the isolation and/or purification of the compounds of the formula I.

On the other hand, compounds of the formula I can be converted into the corresponding metal salts, in
25 particular alkali metal or alkaline earth metal salts, or into the corresponding ammonium salts using bases (e.g. sodium or potassium hydroxide or carbonate). Physiologically acceptable organic bases, e.g. ethanolamine can also be used.

30 Compounds of the formula I according to the invention can be chiral on account of their molecular structure and can accordingly occur in various enantiomeric forms. They can therefore be present in racemic or in
35 optically active form.

Since the pharmaceutical activity of the racemates or of the stereoisomers of the compounds according to the invention can differ, it can be desirable to use the

- 21 -

enantiomers. In these cases, the final product or else even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art, or even
5 employed as such in the synthesis.

In the case of racemic amines, diastereomers are formed from the mixture by reaction with an optically active resolving agent. Suitable resolving agents are, for
10 example, optically active acids, such as the R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitably N-protected amino acids (e.g. N-benzoylproline or N-benzenesulfonylproline) or the
15 various optically active camphorsulphonic acids. Chromatographic resolution of enantiomers with the aid of an optically active resolving agent (e.g. dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chiral
20 derivatized methacrylate polymers attached to silica gel) is also advantageous. Suitable eluents for this are aqueous or alcoholic solvent mixtures such as, for example, hexane/isopropanol/acetonitrile, e.g. in the ratio 82:15:3.

25 The invention further relates to the use of the compounds of the formula I and/or their physiologically acceptable salts for the production of pharmaceutical preparations, in particular in a non-chemical manner.
30 In this connection, they can be brought into a suitable dose form together with at least one solid, liquid and/or semi-liquid excipient or auxiliary and, if appropriate, in combination with one or more other active compounds.

35 The invention further relates to pharmaceutical preparations comprising at least one compound of the formula I and/or one of its physiologically acceptable salts.

- 22 -

These preparations can be used as medicaments in human or veterinary medicine. Possible excipients are organic or inorganic substances which are suitable for enteral (e.g. oral) or parenteral administration or topical application and do not react with the novel compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly. Tablets, pills, sugar-coated tablets, capsules, powders, granules, syrups, juices or drops, in particular, are used for oral administration, suppositories are used for rectal administration, solutions, preferably oily or aqueous solutions, in addition to suspensions, emulsions or implants, are used for parenteral administration, and ointments, creams or powders are used for topical application. The novel compounds can also be lyophilized and the lyophilizates obtained used, for example, for the production of injection preparations. The preparations indicated can be sterilized and/or can contain auxiliaries such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffer substances, colourants, flavourings and/or one or more further active compounds, e.g. one or more vitamins.

The compounds of the formula I and their physiologically acceptable salts can be used in the control and prevention of thromboembolic disorders such as thrombosis, myocardial infarct, arteriosclerosis, inflammations, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication.

In this connection, as a rule the substances according to the invention are preferably administered in doses of between approximately 1 and 500 mg, in particular between 5 and 100 mg, per dose unit. The daily dose is

- 23 -

preferably between approximately 0.02 and 10 mg/kg of bodyweight. The specific dose for each patient depends on all sorts of factors, however, for example on the efficacy of the specific compound employed, on the age, bodyweight, general state of health, sex, on the diet, on the time and route of administration, and on the excretion rate, pharmaceutical combination and severity of the particular disorder to which the therapy applies. Oral administration is preferred.

10

Above and below, all temperatures are indicated in °C. In the following examples, "customary working up" means: water is added, if necessary, the mixture is adjusted, if necessary, depending on the constitution of the final product, to a pH of between 2 and 10 and extracted with ethyl acetate or dichloromethane, the extract is separated off, the organic phase is dried over sodium sulfate and evaporated, and the residue is purified by chromatography on silica gel and/or by crystallization. R_f values on silica gel; eluent: ethyl acetate/methanol 9:1.

15

20

Mass spectrometry (MS): EI (electron impact ionization) M^+
FAB (fast atom bombardment)
($M+H$) $^+$

25


Example 1

140 ml of isobutyric acid and 250 ml of fuming hydrochloric acid are added to 50.0 g of 3,4-diamino-2-chloropyridine. The reaction mixture is heated under reflux for 7 days. It is poured into ice water, the deposited precipitate is separated off and 2-isopropyl-3,5-dihydroimidazo[4,5-c]pyridin-4-one ("AB"), m.p. 310-311° (decomposition), EI 177 is obtained

30

35

- 24 -




"AB".

A mixture of "AB" and 4-chloro-2-isopropyl-3H-imidazo[4,5-c]pyridine is found in the mother liquor.

- 5 A solution of 0.877 g of "AB" and 0.691 g of potassium carbonate in 30 ml of DMF is stirred at room temperature for 30 minutes. 1.5 g of 3-(3-bromo-methylphenyl)-5-methyl[1,2,4]oxadiazole are added and the mixture is stirred for 16 hours and worked up in the customary manner. After chromatography over silica gel, in addition to the two regioisomeric dialkylation products, the compound 2-isopropyl-3-[3-(5-methyl[1,2,4]oxadiazol-3-yl)benzyl]-5H-imidazo[4,5-c]-pyridin-4-one ("CA") is obtained

15



"CA".

An alternative process leads to "CA" as follows (analogously to Mederski et al., J. Med. Chem. 1994, 1632 ff):

- 20 reaction of 3,4-diamino-2-chloropyridine with isobutyric anhydride to give N-(4-amino-2-chloropyridin-3-yl)isobutyramide. The subsequent reaction with 3-(3-bromomethylphenyl)-5-methyl[1,2,4]oxadiazole
- 25 leads to a mixture of 4-chloro-2-isopropyl-3-[3-(5-methyl[1,2,4]oxadiazol-3-yl)benzyl]-3H-imidazo[4,5-c]pyridine and N-(4-amino-2-chloropyridin-3-yl)-N-[3-(5-methyl[1,2,4]oxadiazol-3-yl)benzyl]-isobutyramide. Both compounds are reacted to give "CA".


30

- 25 -

A solution of 0.4 g of "CA" in 10 ml of DMF is mixed with 0.5 g of the compound of the formula III, 258 mg of Cu(II)(OAc)₂ in 50 ml of dichloromethane and 1 g of molecular sieve (0.4 nm), and the mixture is stirred at
5 room temperature for 4 days.

The molecular sieve is removed, and customary work-up gives the compound

2-isopropyl-3-[(5-methyl[1,2,4]oxadiazol-3-yl)-
10 benzyl]-5-(3-cyanophenyl)-3,5-dihydroimidazo-
[4,5-c]pyridin-4-one ("BC1"), 345 mg, m.p. 168°, EI 450



330 mg of BC1 are suspended in 20 ml of ethanol, and
15 490 mg of sodium bicarbonate and 407 mg of hydroxylammonium chloride are then added successively. After further addition of 2 ml of water, the mixture is boiled under reflux for 5 hours. 50 ml of ice-water are added, and customary work-up gives 280 mg of
20 2-isopropyl-3-[(5-methyl[1,2,4]oxadiazol-3-yl)benzyl]-
5-(3-N-hydroxyamidinophenyl)-3,5-dihydroimidazo-
[4,5-c]pyridin-4-one ("BC2"), EI 483.

Analogously, the compound 2-isopropyl-3-(7-cyanonaphth-
25 2-ylmethyl)-5H-imidazo[4,5-c]pyridin-4-one is obtained by reacting the compound "AB" with 2-bromomethyl-7-cyanonaphthalene, followed by work-up. Analogous reaction with the compound of the formula III as described above gives the compound 2-isopropyl-3-(7-
30 cyanonaphth-2-ylmethyl)-5-(3-cyanophenyl)-3,5-dihydro-
imidazo[4,5-c]pyridin-4-one, EI: [M⁺] 443 (74%), 166 (100%).

- 26 -

Subsequent reaction with hydroxylammonium chloride gives 2-isopropyl-3-(7-N-hydroxyamidinonaphth-2-ylmethyl)-5-(3-N-hydroxyamidinophenyl)-3,5-dihydroimidazo[4,5-c]pyridin-4-one, EI: $[M^+]$ 509 (8%), 166 (100%).

Example 2

A solution of 0.27 g of "BC2" in 20 ml of methanol is admixed with 100 mg of Raney nickel and a drop of acetic acid, and the mixture is hydrogenated at room temperature for 8 hours. The catalyst is filtered off and the solvent is removed, giving the compound

2-isopropyl-3-(3-amidinobenzyl)-5-(3-amidinophenyl)-3,5-dihydroimidazo[4,5-c]pyridin-4-one, FAB 428.

The compounds 2-65 of the formula IA listed in Table 1 are obtained analogously to Examples 1 and/or 2




Table 1

No.	R	R ¹	R ²	R ³	n	m.p.	EI (FAB)
2	H	(1)	(1)	H	1	119-120°	
3	Me	(1)	(1)	H	1		
4	Et	(1)	(1)	H	1		
5	t-Bu	(1)	(1)	H	1	>300°	
6	H	(1)	(1)	H	0		
7	Me	(1)	(1)	H	0		
8	Et	(1)	(1)	H	0		
9	i-Pr	(1)	(1)	H	0		
10	t-Bu	(1)	(1)	H	0		

- 27 -

No.	R	R ¹	R ²	R ³	n	m.p.	EI (FAB)
11	H	(1)	(2)	H	0		
12	Me	(1)	(2)	H	0		
13	Et	(1)	(2)	H	0		
14	i-Pr	(1)	(2)	H	0		
15	t-Bu	(1)	(2)	H	0		
16	H	(1)	(2)	H	1	149-150°	
17	Me	(1)	(2)	H	1		
18	Et	(1)	(2)	H	1		
19	i-Pr	(1)	(2)	H	1		
20	t-Bu	(1)	(2)	H	1		
21	H	(3)	(1)	H	1		[M+H] 437 (2%) 131 (100%)
22	Me	(3)	(1)	H	1		
23	Et	(3)	(1)	H	1		[M+H] 464 (8%) 91 (100%)
24	i-Pr	(3)	(1)	H	1		[M+H] 478 (9%) 131 (100%)
25	t-Bu	(3)	(1)	H	1		
26	H	(1)	(4)	H	0		
27	Me	(1)	(4)	H	0		
28	Et	(1)	(4)	H	0		
29	i-Pr	(1)	(4)	H	0		
30	t-Bu	(1)	(4)	H	0		
31	H	(1)	(4)	H	1		
32	Me	(1)	(4)	H	1		
33	Et	(1)	(4)	H	1		
34	i-Pr	(1)	(4)	H	1		
35	t-Bu	(1)	(4)	H	1		
36	H	(1)	(5)	H	0		
37	Me	(1)	(5)	H	0		
38	Et	(1)	(5)	H	0		
39	i-Pr	(1)	(5)	H	0		


- 28 -

No.	R	R ¹	R ²	R ³	n	m.p.	EI (FAB)
40	t-Bu	(1)	(5)	H	0		
41	H	(1)	(5)	H	1		
42	Me	(1)	(5)	H	1		
43	Et	(1)	(5)	H	1		
44	i-Pr	(1)	(5)	H	1		
45	t-Bu	(1)	(5)	H	1		
46	H	(3)	(2)	H	1		
47	Me	(3)	(2)	H	1		
48	Et	(3)	(2)	H	1		
49	i-Pr	(3)	(2)	H	1		
50	t-Bu	(3)	(2)	H	1		
51a	iso-Bu	(10)	(9)	H	1		[M+H] 514 (16%) 223 (100%)
51b	iso-Bu	(10)	(16)	H	1		[M+H] 548 (38%) 166 (100%)
51c	iso-Bu	(3)	(1)	H	1	244°	
52	i-Pr	(6)	(7)	H	1	188°	[M+H] 560 (52%) 424 (100%)
53	Bu	(1)	(1)	H	1	214-215°	
54	Bu	(6)	(8)	H	1	220-221°	
55	Bu	(9)	(9)	H	1	166-167°	
56	Bu	(3)	(1)	H	1	244-245°	
57	Bu	(10)	(8)	H	1	169-170°	
58	Bu	(1)	(4)	H	1	128° (decomp.)	[M+H] 555 (94%) 91 (100%)
59	Bu	(6)	(11)	H	1	175°	
60	Pe	(1)	(1)	H	1	191°	
61	Bu	(12)	(8)	H	1	187-138°	
62	Bu	(13)	(8)	H	1	120-121°	
63	Bu	(13)	(1)	H	1	137-138°	
64	(14)	(15)	(1)	H	1	88-89°	
65	Pe	(15)	(1)	H	1	145°	


- 29 -

(1) = 3-amidinophenyl; (2) = 2-aminosulfonylphenyl;

(3) = 7-amidinonaphth-2-yl;



5



(6) = 3-[(5-methyl-[1,2,4]-oxadiazol-3-yl)phenyl];

(7) = 2-(N-tert-butylaminosulphonyl)phenyl;

(8) = 3-aminocarbonylphenyl;

10 (9) = 3-cyanophenyl;

(10) = 7-[(5-methyl-[1,2,4]-oxadiazol-3-yl)naphth-2-yl];

(11) = 4-bromophenyl;

(12) = 3-(N-tert-butylaminosulphonyl)phenyl;

(13) = 3-aminosulphonylphenyl;

15 (14) = cyclopentylmethyl;

(15) = 1-aminoisoquinolin-7-yl;

(16) = 3-N-hydroxyamidinophenyl;

Me = methyl; Et = ethyl; i-Pr = isopropyl; Bu =
 20 n-butyl; t-Bu = tert-butyl; iso-Bu = isobutyl; Pe =
 Pentyl

The examples below relate to pharmaceutical
 preparations:

25

Example A: Injection vials

A solution of 100 g of an active compound of the
 formula I and 5 g of disodium hydrogen phosphate is
 30 adjusted to pH 6.5 in 3 l of double-distilled water

- 30 -

using 2N hydrochloric acid, sterile-filtered, dispensed into injection vials, lyophilized under sterile conditions and aseptically sealed. Each injection vial contains 5 mg of active compound.

5

Example B: Suppositories

A mixture of 20 g of an active compound of the formula I is fused with 100 g of soya lecithin and 1400 g of cocoa butter, poured into moulds and allowed to cool. Each suppository contains 20 mg of active compound.

10

Example C: Solution

A solution of 1 g of an active compound of the formula I, 9.38 g of $\text{NaH}_2\text{PO}_4 \cdot 2 \text{H}_2\text{O}$, 28.48 g of $\text{Na}_2\text{HPO}_4 \cdot 12 \text{H}_2\text{O}$ and 0.1 g of benzalconium chloride in 940 ml of double-distilled water is prepared. It is adjusted to pH 6.8, made up to 1 l and sterilized by irradiation. This solution can be used in the form of eye drops.

20

Example D: Ointment

500 mg of active compound of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.

25

Example E: Tablets

A mixture of 1 kg of active compound of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed in a customary manner to give tablets, such that each tablet contains 10 mg of active compound.

30

- 31 -

Example F: Sugar-coated tablets

Analogously to Example E, tablets are pressed and are then coated in a customary manner using a coating of
5 sucrose, potato starch, talc, tragacanth and colorant.

Example G: Capsules

2 kg of active compound of the formula I are dispensed
10 into hard gelatin capsules in a customary manner such that each capsule contains 20 mg of the active compound.


Example H: Ampoules

15 A solution of 1 kg of active compound of the formula I in 60 l of double-distilled water is sterile-filtered, dispensed into ampoules, lyophilized under sterile conditions and aseptically sealed. Each ampoule
20 contains 10 mg of active compound.

- 32 -

Patent Claims

1. Compounds of the formula I



5

in which

R is H or unbranched or branched alkyl having 1-6 C atoms or cycloalkyl having 3-6 C atoms,

R¹ is Ar,


R² is Ar',

R³ is H, R, R⁴, Hal, CN, COOH, COOA or CONH₂,

Ar, Ar' are phenyl, naphthyl or biphenyl, in each case independently of one another unsubstituted or mono-, di- or trisubstituted by R, OH, Hal, CN, NO₂, CF₃, NH₂, NHR, NR₂, pyrrolidin-1-yl, piperidin-1-yl, benzyloxy, SO₂NH₂, SO₂NHR, SO₂NR₂, -CONHR, -CONR₂, -(CH₂)_n-NH₂, -(CH₂)_n-NHR, -(CH₂)_n-NR₂, -O-(CH₂)_n-NH₂, -O-(CH₂)_n-NHR, -O-(CH₂)_n-NR₂, R⁴ or together by -O-(CH₂)_m-O-,

or are NH₂-substituted isoquinolinyl, R⁴ is -C(=NH)-NH₂ which is unsubstituted or monosubstituted by -COR, -COOR, -OH or by a conventional amino protective group or -C(=NH)-NH₂ or -NH-C(=NH)-NH₂, -C(=O)-N=C(NH₂)₂,

30



A is alkyl having 1-4 C atoms,

- 33 -

Hal is F, Cl, Br or I,
m is 1 or 2,
n is 0 or 1,
and their salts and solvates.

5

2. Compounds according to Claim 1

a) 2-isopropyl-3-(3-amidinobenzyl)-5-(3-
amidinophenyl)-3,5-dihydroimidazo[4,5-
10 c]pyridin-4-one;
and their salts.

and their salts and solvates.

15 3. Process for preparing compounds of the formula I
according to Claim 1, and their salts,
characterized in that

a) they are set free from one of their
functional derivatives by treating with a
20 solvolysing or hydrogenolysing agent, by

i) liberating an amidino group from its
oxadiazole derivative or oxazolidinone
derivative by hydrogenolysis or
25 solvolysis,

ii) replacing a conventional amino protective
group by hydrogen by treating with a
solvolysing or hydrogenolysing agent or
30 liberating an amino group protected by a
conventional protective group,

or

35 b) in a compound of the formula I, one or more
radicals R, R¹, R² and/or R³ are converted
into one or more radicals R, R¹, R² and/or R³,

by, for example

- 34 -

- i) hydrolysing an ester group to a carboxyl group,
- 5 ii) reducing a nitro group,
- iii) acylating an amino group,
- iv) converting a cyano group into an amidino group
- 10 and/or
- c) a base or acid of the formula I is converted
- 15 into one of its salts.
4. Process for producing pharmaceutical preparations, characterized in that a compound of the formula I according to Claim 1 and/or one of its
- 20 physiologically acceptable salts is brought into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or auxiliary.
- 25 5. Pharmaceutical preparation, characterized in that it comprises at least one compound of the formula I according to Claim 1 and/or one of its physiologically acceptable salts.
- 30 6. Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as pharmaceutically active compounds.
- 35 7. Compounds of the formula I according to Claim 1 and their physiologically acceptable salts for controlling thromboses, myocardial infarct, arteriosclerosis, inflammations, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication.

- 35 -

8. Medicaments of the formula I according to Claim 1
and their physiologically acceptable salts as
inhibitors of the coagulation factor Xa.
- 5 9. Use of compounds of the formula I according to
Claim 1 and/or their physiologically acceptable
salts for producing a medicament.
- 10 10. Use of compounds of the formula I according to
Claim 1 and/or their physiologically acceptable
salts in the control of thromboses, myocardial
infarct, arteriosclerosis, inflammations,
apoplexy, angina pectoris, restenosis after
15 angioplasty and intermittent claudication.

Fetherstonhaugh & Co.
Ottawa, Canada
Patent Agents